ALKERMES | ALKS - Ordinary Share Capital



ALKERMES reported $165.05M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
ALKERMES USD 165.05M 163.25M Jun/2025
Amgen USD 538M 33.04B Jun/2025
Biogen USD 146.6M 146.5M Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
J&J USD 3.12B 0 Mar/2025
Malin Corporation EUR 200K 0 Dec/2024
Merck USD 1.79B 0 Mar/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
Otsuka Holdings JPY 528.13M 81.16B Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025